2004 Archive

Accera Inc., a privately held biotechnology company, announced today the formation of a Clinical Advisory Board (CAB) and Scientific Advisory Board (SAB) to assist in the Company's product development efforts.  Accera is developing a new class of therapeutic products to treat or prevent Alzheimer's disease (AD) and related neurodegenerative diseases that are often associated with aging.

Accera Inc. announced today the appointment of Gary Hooper to its Board of Directors. Mr. Hooper has nearly twenty years of executive management level experience in the biotechnology industry and broad experience in corporate and business development.

Accera Inc. announced today the appointment of Claude H. Nash, Ph.D. to Chairman of the Board.  Dr. Nash has been a leading figure in the biotechnology industry as President of ViroPharma, Inc.  He brings to Accera more than 20 years of executive management experience in the pharmaceutical and biotechnology industries.

Accera, Inc., a drug development company focused on Alzheimer's disease and related neurodegenerative diseases, announced it has recently closed a Series A financing round of $6 million.  The financing was led by inventages Venture Capital GmbH of Geneva, Switzerland and joined by San Diego-based POSCO BioVentures.